UFP Technologies, Inc. (UFPT) Aandelenanalyse

Bedrijfsoverzicht

UFP Technologies, Inc. is a specialized manufacturer that designs and produces engineered custom products, sterile packaging solutions, and protective components specifically for the medical device industry, including items used in robotic surgery and patient care. The company operates within the Healthcare sector, specifically the Medical Devices industry, which positions it to capitalize on advancements in biomedical technology and the ongoing demand for sterile, high-quality medical supplies. Its financial scale is substantial, with a market capitalization of $1.55 billion, annual revenue reaching $602.80 million, and a workforce comprising 4,846 employees. These valuation and revenue figures indicate that the entity holds a significant position within its niche, suggesting a mature operation with established market presence rather than a nascent startup.

Financiële gezondheid

The company reported revenue of $602.80 million over the trailing twelve months, generating a net income of $68.31 million and an EBITDA of $112.18 million. The substantial gap between the $602.80 million revenue and the $68.31 million net income reveals a cost structure where operating expenses, including cost of goods sold, administrative costs, and other operational expenditures, consume approximately 88.7% of total revenue. Free cash flow stands at $65.67 million, indicating that the company generates sufficient cash from its core operations to fund capital expenditures, service debt, and potentially return capital to shareholders without relying on external financing. When analyzing profitability efficiency, the gross margin is 28.3%, reflecting the percentage of revenue remaining after direct production costs; the operating margin of 14.1% shows the profitability from core business operations after overhead; and the profit margin of 11.3% represents the final portion of revenue left as net income after all expenses. Regarding liquidity and leverage, the company holds $20.30 million in cash against $154.48 million in debt, resulting in a debt-to-equity ratio of 36.45, which characterizes a balance sheet that is moderately leveraged given the cash reserve is significantly lower than total debt obligations. The current ratio is 2.69, a metric that indicates strong short-term liquidity as the company possesses more than double the current assets necessary to cover its current liabilities. Furthermore, the return on equity is 17.8% and the return on assets is 9.1%, metrics that reveal management is generating substantial returns on the shareholders' capital and utilizing the company's asset base effectively to generate profit.

Waarderingsbeoordeling

Valuation multiples for UFP Technologies, Inc. show a trailing P/E ratio of 23.00 and a forward P/E of 17.57. The difference between these two figures implies that the market expects earnings growth in the future, as investors are willing to accept a lower multiple on projected earnings compared to historical performance. The price-to-book ratio is 3.66, which indicates that the market values the company at a significant premium over its net asset book value, suggesting confidence in intangible assets or future growth prospects not fully captured on the balance sheet. Alternative valuation metrics provide further context, with a price-to-sales ratio of 2.58 and an EV/EBITDA of 15.03, suggesting the company trades at a moderate multiple relative to its sales and earnings power before interest, taxes, depreciation, and amortization. Price action over the last year has seen the stock range between a 52-week low of $182.87 and a 52-week high of $274.93. Without a specific current share price provided in the source data, the precise percentage position relative to this range cannot be calculated, but the spread between the high and low demonstrates a trading range of approximately $92.06. The beta value is 1.17, meaning the stock's price volatility is higher than the broader market, moving 17% more than the market average during periods of fluctuation.

Growth & Income

Growth metrics indicate a revenue growth year-over-year of 3.4% and an earnings growth year-over-year of 6.8%. The fact that earnings are growing faster than revenue implies that the company is achieving economies of scale, improving operating leverage, or successfully passing on input cost increases to maintain or expand profit margins. Regarding income distribution, the company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Since the payout ratio is zero, the company retains all of its net income, reinvesting earnings back into the business for research, development, capacity expansion, or debt reduction rather than distributing cash to shareholders. This reinvestment strategy aligns with the growth profile of a medical device manufacturer that may prioritize long-term R&D in sterile packaging and engineered custom products. The overall growth and income profile is characterized by steady single-digit revenue expansion, accelerating earnings growth driven by operational efficiency, and a total reinvestment of profits into the core business model rather than dividend payouts.